Alnylam Pharmaceuticals' Cash from Investing Activities rose 1756.55% to $501.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $420.6 million, marking a year-over-year increase of 238.08%. This contributed to the annual value of -$116.8 million for FY2024, which is 65.26% up from last year.
As of Q3 2025, Alnylam Pharmaceuticals' Cash from Investing Activities stood at $501.1 million, which was up 454.44% from -$141.4 million recorded in Q2 2025.
In the past 5 years, Alnylam Pharmaceuticals' Cash from Investing Activities ranged from a high of $501.1 million in Q3 2025 and a low of -$413.4 million during Q4 2021.
Moreover, its 3-year median value for Cash from Investing Activities was -$30.2 million (2024), whereas its average is $1.8 million.
In the last 5 years, Alnylam Pharmaceuticals' Cash from Investing Activities crashed by 775.01% in 2021 and then surged by 1,756.55% in 2025.
Quarterly analysis of 5 years shows Alnylam Pharmaceuticals' Cash from Investing Activities stood at -$413.4 million in 2021, then soared by 66.16% to -$139.9 million in 2022, then tumbled by 72.01% to -$240.7 million in 2023, then skyrocketed by 78.01% to -$52.9 million in 2024, then surged by 1,756.55% to $501.1 million in 2025.
Its Cash from Investing Activities stands at $501.1 million for Q3 2025, versus -$141.4 million for Q2 2025 and $113.8 million for Q1 2025.

Peer Comparison

Historic Data

Download Data 🔒

Date	Value